This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

reputable news agency


High-intensity statins underused with atherosclerotic cardiovascular disease

High-intensity statins underused with atherosclerotic cardiovascular disease

Among patients with atherosclerotic cardiovascular disease (ASCVD), high-intensity statins are underutilized in routine care, according to a study published online Aug. 2 in Circulation: Cardiovascular Quality and Outcomes.

Ann Marie Navar, M.D., Ph.D., from University of Texas Southwestern Medical Center in Dallas, and colleagues examined use of statins and other lipid-lowering therapy (LLT) and changes in (LDL-C) among patients with ASCVD. The analysis included electronic health record-derived data from outpatient visits for 322,153 patients with ASCVD (Cerner Real-World Data from 92 U.S. health systems 2017 through 2018).

The researchers found that 76.1 percent of patients were on statins, with only 39.4 percent on high-intensity statins. Compared with women, men were more likely to receive high-intensity statins (multivariable-adjusted odds ratio [OR], 1.34). Lower odds of statin use were seen with increasing age (OR, 0.79 per five-year increase at 60 years). Compared with patients with , patients with (OR, 0.40) and (OR, 0.75) had lower odds of using high-intensity statins. Most patients (61.3 percent) at baseline had elevated LDL-C (≥70 mg/dL), including 59.8 percent of those on low/moderate-intensity statins and 76.1 percent on no statin. At one year, only 45.3 percent achieved an LDL-C <70 mg/dL. Nonstatin LLT use was low. Among patients on no statin or low/moderate-intensity statin at baseline, at one year, 14.8 and 13.4 percent, respectively, were on high-intensity statins.

"Concerted efforts are needed to address therapeutic inertia for lipid management in patients with ASCVD," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

More information: Ann Marie Navar et al, Gaps in Guideline-Based Lipid-Lowering Therapy for Secondary Prevention in the United States: A Retrospective Cohort Study of 322 153 Patients, Circulation: Cardiovascular Quality and Outcomes (2023). DOI: 10.1161/CIRCOUTCOMES.122.009787

Copyright © 2023 HealthDay. All rights reserved.

Citation: High-intensity statins underused with atherosclerotic cardiovascular disease (2023, September 19) retrieved 15 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Drop in LDL cholesterol greater with low-, moderate-intensity statins for seniors


Feedback to editors